Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BRIVARACETAM

All strengths: Limited Use — Reason for Use code 548 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use — Reason for Use code 548 required
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (N03AX) — coverage varies; not interchangeable

  • Lamotrigine (Lamictal): general benefit
  • Topiramate (Topamax Sprinkle): general benefit, Limited Use 321, Not a benefit
  • Cenobamate (Xcopri): limited Use 719
  • Lacosamide (Vimpat): limited Use 430
  • Levetiracetam (PDP-Levetiracetam): limited Use 473, Limited Use 640, 705
  • Perampanel (Fycompa): limited Use 430, 564

14 more in the class list below

Apo-Brivaracetam · DIN 02538679 · 10mg · tablet

Limited Use — Reason for Use code 548 requiredMarketed · checked 2026-09-02
Write on scriptLU code 548 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 548
Reason for Use code 548 - As adjunctive therapy in the treatment of patients with partial-onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND - Patients are not receiving concurrent therapy with levetiracetam; AND - Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, carbamazepine, gabapentin, lamotrigine, vigabatrin, topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Apo-Brivaracetam · DIN 02538679 Manufacturer: Apotex Inc.; listing date 2024-11-29 Health Canada: Marketed since 2024-09-10 · brand APO-BRIVARACETAM · ATC N03AX23 BRIVARACETAM · form Tablet · route Oral · ingredients BRIVARACETAM 10 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Brivaracetam: Formulary list price $2.3760/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.3760 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102737 · Verify on the e-Formulary ↗ (DIN 02538679)

Source record
DIN 02538679: Apo-Brivaracetam Raw flags: sec12=Y, sec3=Y Item: 281200177; group id 420; item number 1036; lccId 00312; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.3760; ministry $2.3760 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538679 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102737
Interchangeable products
Brivlera · DIN 02452936 · $2.3760
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538679
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Brivlera · DIN 02452936 · 10mg · tablet

Limited Use — Reason for Use code 548 requiredMarketed · checked 2026-09-02
Write on scriptLU code 548 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 548
Reason for Use code 548 - As adjunctive therapy in the treatment of patients with partial-onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND - Patients are not receiving concurrent therapy with levetiracetam; AND - Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, carbamazepine, gabapentin, lamotrigine, vigabatrin, topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Savings card: RxHelp ONE lists Brivlera (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Brivlera · DIN 02452936 Manufacturer: UCB Canada Inc.; listing date 2018-12-21 Health Canada: Marketed since 2016-05-02 · brand BRIVLERA · ATC N03AX23 BRIVARACETAM · form Tablet · route Oral · ingredients BRIVARACETAM 10 MG · company Ucb canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $2.3760 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93933 · Verify on the e-Formulary ↗ (DIN 02452936)

Source record
DIN 02452936: Brivlera Raw flags: sec12=Y, sec3=Y Item: 281200177; group id 420; item number 1036; lccId 00312; manufacturer id UCB Source form: Tab; strength: 10mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $4.3200; ministry $2.3760 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02452936 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93933
Interchangeable products
Apo-Brivaracetam · DIN 02538679 · $2.3760
Shortage status: resolved shortage (ended 2020-06-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02452936
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Brivaracetam · DIN 02538687 · 25mg · tablet

Limited Use — Reason for Use code 548 requiredMarketed · checked 2026-09-02
Write on scriptLU code 548 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 548
Reason for Use code 548 - As adjunctive therapy in the treatment of patients with partial-onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND - Patients are not receiving concurrent therapy with levetiracetam; AND - Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, carbamazepine, gabapentin, lamotrigine, vigabatrin, topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Apo-Brivaracetam · DIN 02538687 Manufacturer: Apotex Inc.; listing date 2024-11-29 Health Canada: Marketed since 2024-09-10 · brand APO-BRIVARACETAM · ATC N03AX23 BRIVARACETAM · form Tablet · route Oral · ingredients BRIVARACETAM 25 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Brivaracetam: Formulary list price $2.3760/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.3760 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102739 · Verify on the e-Formulary ↗ (DIN 02538687)

Source record
DIN 02538687: Apo-Brivaracetam Raw flags: sec12=Y, sec3=Y Item: 281200178; group id 420; item number 1037; lccId 00312; manufacturer id APX Source form: Tab; strength: 25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.3760; ministry $2.3760 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538687 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102739
Interchangeable products
Brivlera · DIN 02452944 · $2.3760
Shortage status: shortage reported ended 2026-04-02 (report last updated 2026-04-02); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538687
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Brivlera · DIN 02452944 · 25mg · tablet

Limited Use — Reason for Use code 548 requiredMarketed · checked 2026-09-02
Write on scriptLU code 548 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 548
Reason for Use code 548 - As adjunctive therapy in the treatment of patients with partial-onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND - Patients are not receiving concurrent therapy with levetiracetam; AND - Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, carbamazepine, gabapentin, lamotrigine, vigabatrin, topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Savings card: RxHelp ONE lists Brivlera (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Brivlera · DIN 02452944 Manufacturer: UCB Canada Inc.; listing date 2018-12-21 Health Canada: Marketed since 2016-05-02 · brand BRIVLERA · ATC N03AX23 BRIVARACETAM · form Tablet · route Oral · ingredients BRIVARACETAM 25 MG · company Ucb canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $2.3760 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93934 · Verify on the e-Formulary ↗ (DIN 02452944)

Source record
DIN 02452944: Brivlera Raw flags: sec12=Y, sec3=Y Item: 281200178; group id 420; item number 1037; lccId 00312; manufacturer id UCB Source form: Tab; strength: 25mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $4.3200; ministry $2.3760 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02452944 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93934
Interchangeable products
Apo-Brivaracetam · DIN 02538687 · $2.3760
Shortage status: resolved shortage (ended 2020-06-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02452944
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Brivaracetam · DIN 02538695 · 50mg · tablet

Limited Use — Reason for Use code 548 requiredMarketed · checked 2026-09-02
Write on scriptLU code 548 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 548
Reason for Use code 548 - As adjunctive therapy in the treatment of patients with partial-onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND - Patients are not receiving concurrent therapy with levetiracetam; AND - Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, carbamazepine, gabapentin, lamotrigine, vigabatrin, topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Brivaracetam · DIN 02538695 Manufacturer: Apotex Inc.; listing date 2024-11-29 Health Canada: Marketed since 2024-09-10 · brand APO-BRIVARACETAM · ATC N03AX23 BRIVARACETAM · form Tablet · route Oral · ingredients BRIVARACETAM 50 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Brivaracetam: Formulary list price $2.1600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.1600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102740 · Verify on the e-Formulary ↗ (DIN 02538695)

Source record
DIN 02538695: Apo-Brivaracetam Raw flags: sec12=Y, sec3=Y Item: 281200179; group id 420; item number 1038; lccId 00312; manufacturer id APX Source form: Tab; strength: 50mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.1600; ministry $2.1600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538695 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102740
Interchangeable products
Auro-Brivaracetam · DIN 02539292 · $2.1600 Brivlera · DIN 02452952 · $2.1600
Shortage status: active shortage (reported 2026-08-18, estimated to end 2026-09-18, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538695
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Brivaracetam · DIN 02539292 · 50mg · tablet

Limited Use — Reason for Use code 548 requiredMarketed · checked 2026-09-02
Write on scriptLU code 548 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 548
Reason for Use code 548 - As adjunctive therapy in the treatment of patients with partial-onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND - Patients are not receiving concurrent therapy with levetiracetam; AND - Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, carbamazepine, gabapentin, lamotrigine, vigabatrin, topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Brivaracetam · DIN 02539292 Manufacturer: Auro Pharma Inc.; listing date 2024-11-29 Health Canada: Marketed since 2024-09-12 · brand AURO-BRIVARACETAM · ATC N03AX23 BRIVARACETAM · form Tablet · route Oral · ingredients BRIVARACETAM 50 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Brivaracetam: Formulary list price $2.1600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.1600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102793 · Verify on the e-Formulary ↗ (DIN 02539292)

Source record
DIN 02539292: Auro-Brivaracetam Raw flags: sec12=Y, sec3=Y Item: 281200179; group id 420; item number 1038; lccId 00312; manufacturer id AUR Source form: Tab; strength: 50mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.1600; ministry $2.1600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02539292 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102793
Interchangeable products
Apo-Brivaracetam · DIN 02538695 · $2.1600 Brivlera · DIN 02452952 · $2.1600
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02539292
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Brivlera · DIN 02452952 · 50mg · tablet

Limited Use — Reason for Use code 548 requiredMarketed · checked 2026-09-02
Write on scriptLU code 548 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 548
Reason for Use code 548 - As adjunctive therapy in the treatment of patients with partial-onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND - Patients are not receiving concurrent therapy with levetiracetam; AND - Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, carbamazepine, gabapentin, lamotrigine, vigabatrin, topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Savings card: RxHelp ONE lists Brivlera (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Brivlera · DIN 02452952 Manufacturer: UCB Canada Inc.; listing date 2018-12-21 Health Canada: Marketed since 2016-05-02 · brand BRIVLERA · ATC N03AX23 BRIVARACETAM · form Tablet · route Oral · ingredients BRIVARACETAM 50 MG · company Ucb canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $2.1600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93935 · Verify on the e-Formulary ↗ (DIN 02452952)

Source record
DIN 02452952: Brivlera Raw flags: sec12=Y, sec3=Y Item: 281200179; group id 420; item number 1038; lccId 00312; manufacturer id UCB Source form: Tab; strength: 50mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $4.3200; ministry $2.1600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02452952 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93935
Interchangeable products
Apo-Brivaracetam · DIN 02538695 · $2.1600 Auro-Brivaracetam · DIN 02539292 · $2.1600
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02452952
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Brivaracetam · DIN 02538709 · 75mg · tablet

Limited Use — Reason for Use code 548 requiredMarketed · checked 2026-09-02
Write on scriptLU code 548 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 548
Reason for Use code 548 - As adjunctive therapy in the treatment of patients with partial-onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND - Patients are not receiving concurrent therapy with levetiracetam; AND - Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, carbamazepine, gabapentin, lamotrigine, vigabatrin, topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Apo-Brivaracetam · DIN 02538709 Manufacturer: Apotex Inc.; listing date 2024-11-29 Health Canada: Marketed since 2024-09-10 · brand APO-BRIVARACETAM · ATC N03AX23 BRIVARACETAM · form Tablet · route Oral · ingredients BRIVARACETAM 75 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Brivaracetam: Formulary list price $2.3760/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.3760 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102741 · Verify on the e-Formulary ↗ (DIN 02538709)

Source record
DIN 02538709: Apo-Brivaracetam Raw flags: sec12=Y, sec3=Y Item: 281200180; group id 420; item number 1039; lccId 00312; manufacturer id APX Source form: Tab; strength: 75mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.3760; ministry $2.3760 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538709 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102741
Interchangeable products
Brivlera · DIN 02452960 · $2.3760
Shortage status: resolved shortage (ended 2026-03-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538709
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Brivlera · DIN 02452960 · 75mg · tablet

Limited Use — Reason for Use code 548 requiredMarketed · checked 2026-09-02
Write on scriptLU code 548 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 548
Reason for Use code 548 - As adjunctive therapy in the treatment of patients with partial-onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND - Patients are not receiving concurrent therapy with levetiracetam; AND - Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, carbamazepine, gabapentin, lamotrigine, vigabatrin, topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Savings card: RxHelp ONE lists Brivlera (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Brivlera · DIN 02452960 Manufacturer: UCB Canada Inc.; listing date 2018-12-21 Health Canada: Marketed since 2016-05-02 · brand BRIVLERA · ATC N03AX23 BRIVARACETAM · form Tablet · route Oral · ingredients BRIVARACETAM 75 MG · company Ucb canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $2.3760 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93936 · Verify on the e-Formulary ↗ (DIN 02452960)

Source record
DIN 02452960: Brivlera Raw flags: sec12=Y, sec3=Y Item: 281200180; group id 420; item number 1039; lccId 00312; manufacturer id UCB Source form: Tab; strength: 75mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $4.3200; ministry $2.3760 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02452960 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93936
Interchangeable products
Apo-Brivaracetam · DIN 02538709 · $2.3760
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02452960
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Brivaracetam · DIN 02538717 · 100mg · tablet

Limited Use — Reason for Use code 548 requiredMarketed · checked 2026-09-02
Write on scriptLU code 548 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 548
Reason for Use code 548 - As adjunctive therapy in the treatment of patients with partial-onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND - Patients are not receiving concurrent therapy with levetiracetam; AND - Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, carbamazepine, gabapentin, lamotrigine, vigabatrin, topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Brivaracetam · DIN 02538717 Manufacturer: Apotex Inc.; listing date 2024-11-29 Health Canada: Marketed since 2024-09-10 · brand APO-BRIVARACETAM · ATC N03AX23 BRIVARACETAM · form Tablet · route Oral · ingredients BRIVARACETAM 100 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Brivaracetam: Formulary list price $2.1600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.1600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102742 · Verify on the e-Formulary ↗ (DIN 02538717)

Source record
DIN 02538717: Apo-Brivaracetam Raw flags: sec12=Y, sec3=Y Item: 281200181; group id 420; item number 1040; lccId 00312; manufacturer id APX Source form: Tab; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.1600; ministry $2.1600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538717 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102742
Interchangeable products
Auro-Brivaracetam · DIN 02539306 · $2.1600 Brivlera · DIN 02452979 · $2.1600
Shortage status: resolved shortage (ended 2026-04-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538717
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Brivaracetam · DIN 02539306 · 100mg · tablet

Limited Use — Reason for Use code 548 requiredMarketed · checked 2026-09-02
Write on scriptLU code 548 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 548
Reason for Use code 548 - As adjunctive therapy in the treatment of patients with partial-onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND - Patients are not receiving concurrent therapy with levetiracetam; AND - Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, carbamazepine, gabapentin, lamotrigine, vigabatrin, topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Brivaracetam · DIN 02539306 Manufacturer: Auro Pharma Inc.; listing date 2024-11-29 Health Canada: Marketed since 2024-09-12 · brand AURO-BRIVARACETAM · ATC N03AX23 BRIVARACETAM · form Tablet · route Oral · ingredients BRIVARACETAM 100 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Brivaracetam: Formulary list price $2.1600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.1600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102794 · Verify on the e-Formulary ↗ (DIN 02539306)

Source record
DIN 02539306: Auro-Brivaracetam Raw flags: sec12=Y, sec3=Y Item: 281200181; group id 420; item number 1040; lccId 00312; manufacturer id AUR Source form: Tab; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.1600; ministry $2.1600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02539306 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102794
Interchangeable products
Apo-Brivaracetam · DIN 02538717 · $2.1600 Brivlera · DIN 02452979 · $2.1600
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02539306
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Brivlera · DIN 02452979 · 100mg · tablet

Limited Use — Reason for Use code 548 requiredMarketed · checked 2026-09-02
Write on scriptLU code 548 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 548
Reason for Use code 548 - As adjunctive therapy in the treatment of patients with partial-onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND - Patients are not receiving concurrent therapy with levetiracetam; AND - Patients are under the care of a physician experienced in the treatment of epilepsy. Note: Less costly anticonvulsant therapies may include the following: Phenytoin, carbamazepine, gabapentin, lamotrigine, vigabatrin, topiramate, etc. Coverage limit: LU Authorization Period: Indefinite
Savings card: RxHelp ONE lists Brivlera (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Brivlera · DIN 02452979 Manufacturer: UCB Canada Inc.; listing date 2018-12-21 Health Canada: Marketed since 2016-05-02 · brand BRIVLERA · ATC N03AX23 BRIVARACETAM · form Tablet · route Oral · ingredients BRIVARACETAM 100 MG · company Ucb canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $2.1600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93937 · Verify on the e-Formulary ↗ (DIN 02452979)

Source record
DIN 02452979: Brivlera Raw flags: sec12=Y, sec3=Y Item: 281200181; group id 420; item number 1040; lccId 00312; manufacturer id UCB Source form: Tab; strength: 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $4.3200; ministry $2.1600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02452979 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93937
Interchangeable products
Apo-Brivaracetam · DIN 02538717 · $2.1600 Auro-Brivaracetam · DIN 02539306 · $2.1600
Shortage status: resolved shortage (ended 2018-05-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02452979
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

CENOBAMATE

· 9 products · Limited Use, codes 719 · strengths: 12.5mg, 25mg, 50mg, 100mg, 150mg, 200mg, 12.5mg & 25mg, 50mg & 100mg, 150mg & 200mg · Tab, Tab - (Starter Kit)

LACOSAMIDE

· 44 products · Limited Use, codes 430 · strengths: 50mg, 100mg, 150mg, 200mg · Tab

LEVETIRACETAM

· 49 products · Limited Use, codes 640, 705 (3), Limited Use, codes 473 (46) · strengths: 100mg/mL, 250mg, 500mg, 750mg, 1000mg · Oral Sol, Tab

PERAMPANEL

· 12 products · Limited Use, codes 430, 564 · strengths: 2mg, 4mg, 6mg, 8mg, 10mg, 12mg · Tab

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Adults, adolescents and children 4 years of age and older: BRIVLERA (brivaracetam) is indicated as adjunctive therapy in the management of partial- onset seizures in patients 4 years of age and older with epilepsy who are not satisfactorily controlled with conventional therapy. BRIVLERA (brivaracetam) solution for injection for intravenous use is an alternative for adults when oral administration is temporarily not feasible. 1.1 Pediatrics Pediatrics (< 4 years of age): The safety and efficacy of BRIVLERA in children under 4 years of age have not been established and its use in this patient population is not indicated (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics (≥ 65 years of age): The clinical experience with BRIVLERA in elderly patients with epilepsy is limited (29 elderly patients aged between 65 and 80 years). No dose adjustment based on age is necessary. In general, dose selection for an elderly patient should be judicious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see 7.1.4 Geriatrics; 4 DOSAGE AND ADMI… https://pdf.hres.ca/dpd_pm/00077250.PDF PM date: March 9, 2016 Source product: BRIVLERA; DIN 02452936; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Brivaracetam · DIN 02538687 Shortage status: shortage reported ended 2026-04-02 (report last updated 2026-04-02); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538687

Check this DIN again

Apo-Brivaracetam · DIN 02538695 Shortage status: active shortage (reported 2026-08-18, estimated to end 2026-09-18, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538695

Check this DIN again